Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence

  title={Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence},
  author={Stefano Tamburin and Marco Faccini and Rebecca Casari and Angela Federico and Laura Morbioli and Enrica Franchini and Luigi Giuseppe Bongiovanni and Fabio Lugoboni},
  journal={Journal of Psychopharmacology},
  pages={1369 - 1373}
High-dose benzodiazepine (BZD) dependence represents an emerging and under-reported addiction phenomenon and is associated with reduced quality of life. To date there are no guidelines for the treatment of high-dose BZD withdrawal. Low-dose slow flumazenil infusion was reported to be effective for high-dose BZD detoxification, but there is concern about the risk of convulsions during this treatment. We evaluated the occurrence of seizures in 450 consecutive high-dose BZD dependence patients… Expand
High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde
The large prevalence of high-dose LMZ abusers in Italy may be strongly related to the availability and characteristics of oral formulation that may transform the innocuous Dr. Jekyll tablets into an evil Mr. Hyde. Expand
High-Dose Dependence and Cognitive Side Effects to Medical Prescription of Etizolam
The findings suggest that abuse and dependence liability of etizolam should be considered a public health and social problem and offer preliminary evidence on the cognitive side effects of etIZolam high-dose use. Expand
Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data
Although flumazenil shows promising efficacy in the management of benzodiazepine use disorders and withdrawal, more randomized control trials are required before a definitive recommendation can be made around its use. Expand
Detoxification Improves Multidomain Cognitive Dysfunction in High-Dose Benzodiazepine Abusers
It is confirmed that all neuropsychological domains were significantly and profoundly impaired by high-dose BZD abuse and documented that cognitive abnormalities improved after detoxification with slow subcutaneous infusion of flumazenil. Expand
Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring
A customized detoxification procedure driven not only by the intensity of withdrawal symptoms but also by serum BZD monitoring may prevent some failures and make detoxification from BZDs more reliable and effective. Expand
Adult Attention-Deficit/Hyperactivity Disorder and Quality of Life in High-Dose Benzodiazepine and Related Z-Drug Users
QoL was worse in high-dose BZD/Z-drug users than the general population, and the ADHD+ group showed significantly worse QoL measures than the ADHD− group. Expand
Benzodiazepine use and HIV-associated neurocognitive impairment: which comes first?
The association between current benzodiazepine (BZD) use and HIV-associated neurocognitive impairment (NCI) in people living with HIV was examined, and it was found that BZD use increased more than twice the risk of NCI, with similar findings in aviremic participants. Expand
Adult attention-deficit/hyperactivity disorder symptoms, cognitive dysfunction and quality of life in high-dose use of benzodiazepine and Z-drug
High-dose use of benzodiazepines (BZDs) and Z-drugs was found to be associated with adult attention deficit/hyperactivity disorder (ADHD) and multidomain cognitive deficits, but the interplay betweenExpand
Benzodiazepine abuse among athletes: Pain relief or just a weapon against insomnia? A clinical case study
A 30‐year‐old female elite athlete developed lormetazepam addiction after increasing her daily benzodiazepine dosage in an attempt to achieve better sleep and enhanced performances during training. Expand
Therapie der Benzodiazepinabhängigkeit
Langzeitverordnungen von Benzodiazepinen entfallen vor allem auf ältere und weibliche Patienten. Entzugsbehandlungen sollten schrittweise über einen mehrwöchigen Zeitraum erfolgen. BegleitendeExpand


Benzodiazepine dependence and its treatment with low dose flumazenil
Preliminary in vitro water bath and in vivo biocompatibility data in sheep show that such an implant is feasible and so is likely to be used in clinical trials in the near future, and could be capable of managing both acute and longer term benzodiazepine withdrawal sequelae. Expand
Intravenous flumazenil infusion to treat benzodiazepine dependence should be performed in the inpatient clinical setting for high risk of seizure
Flu-I appears to be a highly effective treatment resulting in withdrawal discomfort of lesser severity than any other treatment cessation currently available but, in the authors' opinion, FLU-I is not so safe as suggested by Hood et al. Expand
Slow subcutaneous infusion of flumazenil for the treatment of long-term, high-dose benzodiazepine users: a review of 214 cases
The data support FLU-SSI as a possible efficient strategy for the treatment of patients with long-term, high-dose benzodiazepine addiction, and could become a routine therapy as long as the necessary further studies on dose, duration of infusion and safety issues are carried out. Expand
High dose benzodiazepine dependence: Description of 29 patients treated with flumazenil infusion and stabilised with clonazepam
A case series of benzodiazepine detoxification by flumazenil infusion, stabilised with clonazepam is presented, finding that more than two-thirds of the subjects tolerated the procedure well and about half had a good long term response. Expand
Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study
The effectiveness of FLU may reflect its capacity to upregulate BZD receptors and to reverse the uncoupling between the recognition sites of BzD and GABA, on the GABA A macromolecular complex, that has been reported in tolerant subjects. Expand
Flumazenil use in benzodiazepine overdose in the UK: a retrospective survey of NPIS data
Fumazenil is used infrequently in the management of BZD OD in the UK and was effective and associated with a low incidence of seizure, comparing favourably with the results of published randomised controlled trials and cohort studies. Expand
Focal nonconvulsive seizures during detoxification for benzodiazepine abuse
Two patients with no previous history of seizures or evidence of intracerebral lesions who, during detoxification for benzodiazepine abuse, developed repetitive focal nonconvulsive seizures instead of generalized seizures, even with appropriate doses of preventive AED therapy are described. Expand
Temporary abolition of seizure activity by flumazenil in a case of valproate-induced non-convulsive status epilepticus
We report on a 33-year-old female suffering from frequent complex-partial seizures who developed a non-convulsive status epilepticus after one week of antiepileptic therapy with valproate (VPA) whichExpand
Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication--A Systematic Review with Meta-Analyses of Randomised Trials.
The use of flumazenil in a population admitted at the emergency department with known or suspected benzodiazepine intoxication is associated with a significantly increased risk of (S)AEs compared with placebo, and the harms and benefits should be considered carefully in every patient. Expand
The effect of oral flumazenil on interictal epileptic activity: results of a double-blind, placebo-controlled study
It is suggested that oral flumazenil may have an intrinsic antiepileptic activity and provide a rationale for a new approach in the treatment of intractable epilepsy. Expand